Products for Research Use Only

Research Grade Etokimab

CAT: 1220-DHB74001Size: 100 μgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:1220-DHB74001Size:100 μg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ANB020, now called etokimab, is currently in phase 2a testing in eczema, which is also known as atopic dermatitis. Scientists from the Medical Research Council Human Immunology Unit at the University of Oxford released data from 12 patients showing that 83% who were treated with etokimab reported a reduction in disease severity after 29 days. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. Etokimab is designed to block interleukin-33 (IL-33), an immune-signaling molecule. In peanut allergy, the body overreacts to peanuts as IL-33 activates an antibody called immunoglobin E. These antibodies cause allergic response such as mouth itchiness, hives, breathing difficulties and potentially fatal anaphylactic shock.
Product Name Alternative
ANB020, CAS: 2022981-44-6, IL33
Accession Number
O95760
Expression System
Mammalian Cells
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.
Endotoxin
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Form
Liquid
Buffer
0.01M PBS, pH 7.4.
Notes
For research use only. Not suitable for clinical or therapeutic use.